Survey of the impact of BOLT-trial data on oncologists’ and dermatologists’ decision-making in treating patients with locally advanced basal cell carcinoma
https://doi.org/10.4081/dr.2024.9882
Accepted: 10 March 2024
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Basal cell carcinoma (BCC) is the most common malignant tumour in white populations. Multiple studies demonstrated that the aberrant activation of Hedgehog signaling is a driver of BCC development, and its blockade represents a potential therapeutic target. In Italy, clinicians can prescribe Hedgehog inhibitors (HhIs) Vismodegib and Sonidegib. To highlight the treatment choice of clinicians, we conducted an online survey between November 1 and November 18, 2020 with 33 Italian clinicians from 27 reference hospitals, in which each participant received an anonymous survey consisting of two multiple-choice questions on clinical efficacy and safety profile of Sonidegib and Vismodegib. Respondents reported their opinions on which efficacy and tolerability data of the pivotal phase-II BOLT trial were more relevant in the treatment choice of patients with locally advanced BCC (laBCC). This survey shows that overall response rate (ORR) and the duration of response (DoR) are the most expected across dermatologists and oncologists. The different pharmacokinetic profile of the two HhIs are behind their diverse toxicity spectrum, dose and schedule modification seem to address the choice between vismodegib and sonidegib among dermato-oncology prescribers.
Basal Cell Skin Cancer, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology.
Peris K, Fargnoli MC, Garbe C, et al. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. Eur J Cancer. 2019 Sep;118:10-34. DOI: https://doi.org/10.1016/j.ejca.2019.06.003
Dummer R, Ascierto PA, Basset-Seguin N, et al. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. J Eur Acad Dermatol Venereol (2020). 10.1111/jdv.16230. DOI: https://doi.org/10.1111/jdv.16230
Fania L, Didona D, Morese R, et al. Basal Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines. 2020;8:449. DOI: https://doi.org/10.3390/biomedicines8110449
Sekulic A, Migden MR, Oro AE et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012; 366: 2171–2179. DOI: https://doi.org/10.1056/NEJMoa1113713
Migden MR, Guminski A, Gutzmer R et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol 2015; 16: 716–728. DOI: https://doi.org/10.1016/S1470-2045(15)70100-2
Erivedge EMA Summary of product characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/erivedge-epar-product-information_en.pdf, checked on 31 January 2021.
Odomzo EMA Summary of product characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/odomzo-epar-product-information_en.pdf, checked on 31 January 2021.
Sekulic A, Migden MR, Lewis K et al. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol 2015; 72: 1021–1026. DOI: https://doi.org/10.1016/j.jaad.2015.03.021
Lear JT, Migden MR, Lewis KD et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol 2018; 32: 372–381. DOI: https://doi.org/10.1111/jdv.14542
Sekulic A, Migden MR, Basset-Seguin N, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer (2017) 17(1):332. DOI: https://doi.org/10.1186/s12885-017-3286-5
Dummer R, Guminksi A, Gutzmer R, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br. J. Dermatol. 2020;182:1369–1378 DOI: https://doi.org/10.1111/bjd.18552
Tay EY, Teoh YL, Yeo MS. Hedgehog pathway inhibitors and their utility in basal cell carcinoma: a comprehensive review of current evidence. Dermatol Ther (Heidelb). 2018;9(1):33–49. DOI: https://doi.org/10.1007/s13555-018-0277-7
Ally MS, Aasi S, Wysong A, et al. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. J Am Acad Dermatol. 2014 Nov;71(5):904-911.e1. DOI: https://doi.org/10.1016/j.jaad.2014.05.020
Chang ALS, Tran DC, Cannon JGD, et al. Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-ofconcept study. J Am Acad Dermatol 2019; 80: 564–66).
Stratigos AJ, Sekulic A, Peris K, et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021 Jun;22(6):848. DOI: https://doi.org/10.1016/S1470-2045(21)00126-1
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
